Porton Pharma Solutions
博腾股份
Executive Summary
Porton Pharma Solutions is a Chongqing-based small molecule CDMO specializing in API and intermediate manufacturing for global pharmaceutical companies. The company faces significant BIOSECURE risk due to congressional pressure, making it a potentially problematic partner for US pharma companies despite its manufacturing capabilities. Limited public information suggests a traditionally conservative Chinese pharma company structure focused on contract manufacturing rather than proprietary drug development.
Structure: Porton appears to be a relatively straightforward listed Chinese company on the Shenzhen Stock Exchange with direct operating subsidiaries in mainland China. The lack of complex VIE structures or extensive international holding company layers may simplify due diligence, though standard PRC regulatory and ownership verification will still be required.
Latest Financials
Revenue: 2125237714.06, Net Profit: -206429638.26. Source: East Money (300363)
Period: 2024-09-30 | Source: eastmoney
Ownership & Shareholder Structure
Subsidiaries & Affiliates(1)
| Entity | Type | Jurisdiction | Scope | Flags | BIOSECURE |
|---|---|---|---|---|---|
Porton Pharma (Chongqing) 重庆博腾制药科技股份有限公司 | operating | mainland china | Small molecule CDMO. API and intermediate manufacturing for global pharma. | CDMO | DIRECT |
Corporate Events
博腾股份：关于职工代表大会选举产生第六届董事会职工代表董事的公告
CNINFO announcement for Porton Pharma Solutions (300363.SZ)
博腾股份：关于实际控制人部分股份质押及解除质押的公告
CNINFO announcement for Porton Pharma Solutions (300363.SZ)
博腾股份：关于实际控制人部分股份质押及解除质押的公告
CNINFO announcement for Porton Pharma Solutions (300363.SZ)
博腾股份：关于与关联方形成共同投资暨关联交易的进展公告
CNINFO announcement for Porton Pharma Solutions (300363.SZ)
博腾股份：关于参与认购投资基金份额的进展公告
CNINFO announcement for Porton Pharma Solutions (300363.SZ)
Porton Pharma Solutions Financial Report
Revenue: 2125237714.06, Net Profit: -206429638.26. Source: East Money (300363)
BIOSECURE Risk
Company faces direct congressional pressure regarding BIOSECURE Act inclusion and has direct exposure through its mainland China CDMO operations serving global pharma clients
Key Exposures:
- •Congressional pressure for BIOSECURE designation
- •Direct mainland China API/intermediate manufacturing operations
- •Existing relationships with global pharma companies that could be impacted
Mitigation: No publicly available information on BIOSECURE mitigation efforts or compliance strategies
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent out-licensing deals recorded - company appears focused on CDMO services rather than proprietary development
Approach: Extreme caution recommended. Any engagement should be preceded by thorough BIOSECURE risk assessment and legal review. Consider alternative CDMO partners with lower regulatory risk.
Red Flags
- ⚠BIOSECURE congressional pressure creates regulatory uncertainty
- ⚠Limited transparency on corporate structure and key personnel
- ⚠Lack of recent corporate events or public communications
- ⚠Potential supply chain vulnerabilities for US partners
Quick Facts
- Key People
- 0
- Subsidiaries
- 1
- CDMO/CRO Subs
- 1
- Genomics Subs
- 0
- Direct BIOSECURE
- 1
- Corp Events
- 6
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 3
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: HKEX annual reports, HKEX Disclosure of Interests
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.